Lysine and threonine plasma concentrations in lyorian patients living with human immunodeficiency virus

Lydie Boyvin^{1,2}, Kipré Laurent Séri^{1,2}, Jeanne Armande Aké^{1,2}, Alexis Bahi Gnogbo^{1,2}, Yapi Guillaume Yayé^{1,3} and Joseph Allico Djaman^{1,2},

1 Department of Clinical and Fundamental Biochemistry, Institut Pasteur of Côte d'Ivoire (IPCI) 01 BP 490 2 UFR Biosciences, University Félix Houphouët-Boiany (UFHB) Abidian, 01 BP V34 Abidian, Côte d'Ivoire 3 University Jean Lourougnon Guédé, Côte d'Ivoire, 01 BP 540 Abidjan 01 Côte d'Ivoire

Introduction

Côte d'Ivoire is one of the most affected countries purposes, written consent was obtained from patients in West Africa with HIV/AIDS, with a prevalence for the use of their blood samples taken during of 3.4%. Essential amino acids are needed by the biological monitoring organism as they play key roles in the immune Statistical analysis

statistically significant.

= 0.8640).

Results 1

system and they are supplied through diet. The objective of this study was to determine the plasma lysine and threonine status for bette medical and nutritional management of patients living with HIV.

Methods

This study involved 254 individuals: 127 HIV positive and 127 HIV negative (serving as controls) after confirmation of their HIV status through an HIV test (test DETERMINE® and GENIE II). Lysine and threonine were assayed using high performance liquid chromatography (HPLC) on plasma and CD4 lymphocyte count by the method of flow cytometry (FacsCalibur) from whole blood containing EDTA.

Ethical considerations

The study was conducted in accordance with the Helsinki Declaration 2000 on HIV and AIDS research conducted in poor countries and in accordance with the local legislation regarding the national program on treatment management for People Living with HIV/AIDS (Decree No. 411 of December 23, 2001). The blood samples were collected from HIV-positive patients monitored at the Institut Pasteur of Côte d'Ivoire (IPCI), a reference center for public health programs in



Results 2

In HIV infected male, mean concentrations of lysine and threonine were significantly lower, 97 ± 3.00 and 329 ± 27.36 µmol/L, respectively, as compared to the control (Table 1). However, in HIV infected females, average concentrations of lysine and threonine were respectively higher (173 ± 19.61 and 320 ± 49.05 µmol/L) as compared to the controls (83 ± 5.27 and 243 ± 36.32 µmol/L) with a significant difference for lysine (P < 0.0001) and non-significance for threonine (P = 0.2101) (Table 1).

Relating to HIV infection: Concerning lysine, 50.4% (64/127) of HIV-infected patients and 54.3% (69/127) of the control subjects had lvsine deficiency. On the other hand, 9 (7.10%) samples from HIV patients had excess of lysine, as opposed to the control subjects that showed no excess in lysine concentration (Table 2). Concerning threonine, 9.5% of both HIV patients and controls (12/127) had threonine deficiency; however, 61.4% (78/127) of the HIV-infected patients and 72.4% (92/127) of the controls had excess threonine (Table 2). Finally, the number of HIV infected patients having lysine deficiency (64/127) was higher than those having threonine deficiency (12/127) (Table 2).

Relating to the WHO classification of CD4 lymphocytes: In HIV-infected female who had CD4 lymphocytes >500 and between 350 and 499 cells/mm3, the amino acid concentrations were normal for lysine (243 and 143 µmol/L, respectively) with a significant difference (P < 0.05) and higher for threonine (296 and 443 µmol/L) with no significant difference (P > 0.05) as compared to the

#JIBinnov19

Lysine and threonine plasma concentrations in Ivorian patients living with human immunodeficiency virus

Lydie Boyvin^{1,2}, Kipré Laurent Séri ^{1,2}, Jeanne Armande Aké ^{1,2}, Alexis Bahi Gnogbo ^{1,2}, Yapi Guillaume Yayé ^{1,3} and Joseph Allico Djaman^{1,2},

1 Department of Clinical and Fundamental Biochemistry, Institut Pasteur of Côte d'Ivoire (IPCI) 01 BP 490 2 UFR Biosciences, University Félix Houphouët-Boigny (UFHB) Abidjan, 01 BP V34 Abidjan, Côte d'Ivoire 3 University Jean Lourougnon Guédé, Côte d'Ivoire, 01 BP 540 Abidjan 01 . Côte d'Ivoire

normal reference values (lysine: 107 to 244 μ mol/L; threonine: 74 to 175 μ mol/L). However, when CD4 lymphocytes count was <200 cells/mm3 and between 200 and 349 cells/mm3, these values were lower for lysine (87 and 104 μ mol/L, respectively). In the case of threonine, these values were higher (350 μ mol/L) with a CD4 range of 200 to 349 cells/mm3 (P < 0.05)

and lower (107 μ mol/L) with a CD4 range < 200 cells/mm3 (P > 0.05) (Table 3a). In HIV-infected male, mean concentrations of lysine were normal (126 μ mol/L) with CD4 range > 500 cell/mm3 and reduced with CD4 < 500 cells/mm3 (P > 0.05). The mean concentrations of threonine was high in any CD4 range with no significant difference in all cases (P > or = 0.05) (Table 3b). Finally, according to CD4 lymphocytes count, the correlation is significant for lysine (P = 0.0006) and not significant for threonine (P = 0.8640) (Table 4).

Table 1. Concentrations of L-lysine and L-threonine in HIV patients and controlpopulation according to gender

	PLIHIV	Control	P- values*	PLIHIV	Control	P-values*
L-lysine (107 – 244 µmol/L)	97 ± 3.00	115 ± 4.27	0.0012	173 ± 19.61	83 ± 5.27	< 0.0001
L- threonine (74 – 175 µmol/L)	329 ± 27.36	697 ± 23.31	< 0.0001	320 ± 49.05	243 ± 36.32	0.2101

The difference is significance for P < 0.05

Table 2. Distribution of PLHIV and controls basedon mean concentrations in L-lysine and L-threonine				
Essential amino acids	PLIHIV (n = 127)	Control (n = 127)		
L-lysine				
< 107 µmol/L	64 (50.4%)	69 (54.3%)		
107-244 µmol/L	54 (42.5%)	58 (45.7%)		
> 244 µmol/L	9 (7.1%)	0 (0%)		
L-threonine				
< 74 µmol/L	12 (9.5%)	12 (9.5%)		
74-175 µmol/L	37 (29.1%)	23 (18.1%)		
> 175 µmol/L	78 (61.4%)	92 (72.4%)		

* The difference is significance for P < 0.05

Table 3a. Average concentrations of L-lysine and L-threonine in HIV-infected women according to CD4+ count

CD4⁺ Range	PLHIV female (n = 70)	L-lysine		L-threonine	
		Mean concentration (µmol/L)	Chi2 P*	Mean concentration (µmol/L)	Chi2 P*
> 500	35	243 ± 27.86	0.00	296 ± 27.86	0.87
499 – 350	17	143 ± 8.09	0.03	443 ± 67.76	0.70
349 – 200	07	104 ± 1.09	0.03	350 ± 3.57	0. 03
< 200	11	87 ± 0.49	0.64	107 ± 0.81	0.18
* The difference is significance for $P < 0.05$					

Table 3b. Average concentrations of L-lysine and Lthreonine in HIV-infected men according to CD4+ count

CD4⁺ Range	PLHIV male	L-lysine		L-threonine	
	(n = 57)	Mean concentration (µmol/L)	Chi2 P*	Mean concentrati on (µmol/L)	Chi2 P*
> 500	20	126 ± 0.83	0.29	473 ± 18.84	0.05
499 - 350	11	96 ± 0.17	0.46	273 ± 6.69	0.38
349 – 200	13	92 ± 0.74	0.85	249 ± 20.42	0.72
< 200	13	83 ± 0.18	0.84	322 ± 1.13	0.47

The difference is significance for $\mathsf{P}<0.05$

Table 4: Correlation between CD4+T lymphocytes cellsand plasma amino acids in HIV infected patients.

Amino acids	CD4+ T lymphocytes count			
	Correlation	P value		
Lysine	r = 0.840	0.0006*		
Threonine	r = 0.056	0.8640		

r Value denotes degree of positive or negative correlation; *P denotes statistically significant value; the difference is significant at P < 0.05

Conclusion

The deficiencies observed in HIV positive patients on antiretroviral therapy are therefore due to viral infection and insufficient nutritional intake of lysine. The threonine level depends on the degradation of the health condition of the subject. Therefore, effective early nutritional management of lysine and threonine is very essential to slow down viral replication in order to achieve a better quality of life for patients living with HIV.

References

 Bender DA (2012). Amino Acids Synthesized from Aspartate: Lysine, Methionine (and Cysteine), Threonine and Isoleucine. In: Amino acid metabolism, 3rd ed, John Wiley & Sons, Ltd. pp. 225-277.
Bishop ML, Fody EP, Schoeff LE (2013). Amino acids and proteins. In: Clinical chemistry: Principles, Techniques, Correlations. 7th ed., Wolters Kluwer/Lippincott Williams & Wilkim, Philadelphia, USA. pp. 205-206.
Boyvin L, M'boh G, Aké-Edjème A, Soumahoro-Agbo MK, Séri KL, Djaman J (2013). Serum level of two antioxidant vitamins (A and E) in Ivorian (Côte d'Ivoire) people living with human immunodeficiency virus. Ann. Biol. Res. 4(11):48-54
Butorov EV (2013). Relationship between plasma L-lysine

4.Butorov EV (2013). Relationship between plasma L-lysine concentrations and levels of HIV-1 RNA. Virulence 4:646-653. 5.Faure M, Choné F, Mettraux C, Godin JP, Bécherau F, Vuichoud J, Papet I, Breuille D, Obled C (2007). Threonine utilization for synthesis of acute phase proteins, intestinal proteins, and mucins is increased during sepsis in rats. J. Nutr. 137(7):1802-1807.

6.Ghosh S, Smriga M, Vuvor F, Suri D, Mohammed H, Armah SM, Scrimshaw NS (2010). Effect of lysine supplementation on health and morbidity in subjects belonging to poor periurban households in Accra, Ghana. Am. J. Clin. Nutr. 92(4):928-939.

7. Hallen A, Jamie JF, Cooper AJ (2013). Lysine metabolism in mammalian brain: an update on the importance of recent discoveries. Amino Acids 45(6):1249-1272. Laforgerie

